Trial Search Results

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) in phase 1 and to determine the combined response rate of clinical response CR and very good partial response (VGPR) in phase 2 of oral (PO) ixazomib administered twice-weekly in combination with lenalidomide and low-dose dexamethasone in a 21-day cycle in participants with newly diagnosed multiple myeloma (NDDM).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: Ixazomib
  • Drug: Lenalidomide
  • Drug: Dexamethasone

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   - Male or female patients 18 years or older

   - Symptomatic multiple myeloma or asymptomatic myeloma with myeloma-related organ damage
   diagnosed according to standard criteria

   - Measurable disease as specified in study protocol

   - Hematologic, liver, and renal function as specified in the study protocol.

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

   - Female patients who are post menopausal, surgically sterile, or agree to practice 2
   effective methods of contraception or agree to abstain from heterosexual intercourse;
   must also adhere to the guidelines of the lenalidomide pregnancy prevention program

   - Male patients who agree to practice effective barrier contraception or agree to
   abstain from heterosexual intercourse AND must adhere to the guidelines of the
   lenalidomide pregnancy prevention program

   - Must be able to take concurrent aspirin 325 mg daily

   - Voluntary written consent

Exclusion Criteria

   - Peripheral neuropathy that is greater or equal to Grade 2

   - Female patients who are lactating or pregnant

   - Major surgery or radiotherapy within 14 days before the first dose of study drug

   - Uncontrolled infection requiring systematic antibiotics within 14 days before the
   first dose of study drug

   - Diarrhea (> Grade 1)

   - Prior systemic therapy for multiple myeloma, including investigational drugs (prior
   treatment with corticosteroids or localized radiation therapy dose not disqualify the
   patient)

   - Systemic treatment with strong inhibitors of CYP1A2, strong inhibitors of CYP3A, or
   strong CYP3A inducers, or use of Ginkgo biloba or St. John's wort within 14 days
   before the first dose of study treatment

   - Central nervous system involvement

   - Diagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS
   syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or
   myeloproliferative syndrome

   - Evidence of current uncontrolled cardiovascular conditions

   - Prior or concurrent deep vein thrombosis or pulmonary embolism

   - Known human immunodeficiency virus (HIV) positive, hepatitis B surface
   antigen-positive status, or known or suspected active hepatitis C infection

   - Serious medical or psychiatric illness that could, in the investigator's opinion,
   potentially interfere with the completion of treatment according to the protocol

   - Known allergy to any of the study medications

   - Known gastrointestinal condition or procedure that could interfere with swallowing or
   the oral absorption, or tolerance of IXAZOMIB

   - Diagnosed or treated for another malignancy within 2 years before the first dose or
   previously diagnosed with another malignancy and have any evidence of residual disease
   with the exception of nonmelanoma skin cancer or any completely resected carcinoma in
   situ

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting